Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

Kang Moon Lee, Yoon Tae Jeen, Ju Yeon Cho, Chang Kyun Lee, Ja Seol Koo, Dong Il Park, Jong Pil Im, Soo Jung Park, You Sun Kim, Tae Oh Kim, Suck Ho Lee, Byung Ik Jang, Ji Won Kim, Young Sook Park, Eun Soo Kim, Chang Hwan Choi, Hyo Jong Kim

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background/Aims: Infliximab is currently used for the treatment of moderate-to-severe ulcerative colitis (UC) with an inadequate response to conventional agents. The efficacy and safety of infliximab in Korean patients with UC were assessed. Methods: This was a retrospective multicenter study including all adult patients who received at least one infliximab infusion for UC. Short- and long-term clinical outcomes and adverse events of infliximab therapy were evaluated, and predictors of response were identified. Results: A total of 134 UC patients were included. The indications for infliximab therapy were acute severe UC in 28%, steroid-dependency in 38%, and steroid-refractoriness in 33%, respectively. The rates of clinical response and remission were 87% and 45% at week 8. In multivariate analysis, we found significant predictors of clinical remission at week 8: immunomodulator-naïve (odds ratio [OR]=4.89, 95% confidence interval [CI]: 1.44-16.66, P=0.01), hemoglobin≥11.5g/dL (OR=4.47, 95% CI: 1.48-13.45, P=0.008), C-reactive protein≥3mg/dL (OR=4.77, 95% CI: 1.43-15.94, P=0.01), and response at week 2 (OR=20.54, 95% CI: 2.40-175.71, P=0.006). Long-term clinical response and remission rates were 71% and 52%, respectively, and mucosal healing was the only factor influencing long-term response. Adverse events related to infliximab occurred in 15% of patients, and most of them were mild and transient. Conclusions: Infliximab is effective and safe in the treatment of active UC in Korea. No history of previous immunomodulator use and high baseline C-reactive protein are independent predictors of good response.

Original languageEnglish
Pages (from-to)1829-1833
Number of pages5
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume28
Issue number12
DOIs
Publication statusPublished - 2013 Dec

Keywords

  • Efficacy
  • Infliximab
  • Predictor of response
  • Safety
  • Ulcerative colitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study'. Together they form a unique fingerprint.

  • Cite this

    Lee, K. M., Jeen, Y. T., Cho, J. Y., Lee, C. K., Koo, J. S., Park, D. I., Im, J. P., Park, S. J., Kim, Y. S., Kim, T. O., Lee, S. H., Jang, B. I., Kim, J. W., Park, Y. S., Kim, E. S., Choi, C. H., & Kim, H. J. (2013). Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study. Journal of Gastroenterology and Hepatology (Australia), 28(12), 1829-1833. https://doi.org/10.1111/jgh.12324